Cosmos Holdings

Cosmos Health, Inc. is a pharmaceutical company, which engages in the importation, exportation, distribution, and sale of pharmaceutical products. It is also involved in the research and development of its business units, and acquisition of pharmaceutical companies. The firm offers over-the-counter drugs, branded and generic medicines, and dietary and vitamin supplements. The company was founded on July 21, 2009 and is headquartered in Chicago, IL.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q2 2024

Earnings data Q1 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cosmos Health, Inc. is a pharmaceutical company, which engages in the importation, exportation, distribution, and sale of pharmaceutical products. It is also involved in the research and development of its business units, and acquisition of pharmaceutical companies. The firm offers over-the-counter drugs, branded and generic medicines, and dietary and vitamin supplements. The company was founded on July 21, 2009 and is headquartered in Thessaloniki, Greece.

CHICAGO, IL / ACCESSWIRE / March 24, 2022 / Cosmos Holdings, Inc. ("the Company") (NASDAQ:COSM) , an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, announced today that it will be presenting at the Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m.

Cosmos Holdings to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest

CHICAGO, IL / ACCESSWIRE / March 23, 2022 / Cosmos Holdings, Inc. ("the Company") (Nasdaq:COSM) , an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, provides the following letter to its shareholders from CEO Greg Siokas: "To our valued shareholder, On February 28, 2022, we achieved historic milestones for our Company by uplisting to the Nasdaq Stock Market and concurrently raising $6 million. This was a direct result of intensive analysis, planning and hard work by our Board of Directors and leadership team in 2021.

Cosmos Holdings CEO Provides Letter to Shareholders

CHICAGO, IL / ACCESSWIRE / March 11, 2022 / Cosmos Holdings, Inc. ("the Company") (NASDAQ:COSM) , an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, announced today it will celebrate its recent listing on the Nasdaq Stock Market by ringing the Nasdaq Closing Bell in Times Square, New York City. Cosmos Holdings commenced trading on the Nasdaq under the ticker symbol "COSM" on February 28, 2022.

Cosmos Holdings to Ring Closing Bell Today to Celebrate Milestone NASDAQ Listing

CHICAGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the Company") (Nasdaq: COSM), an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, today announced the closing of a private placement offering to certain institutional investors and an insider of the Company to purchase 6,000 shares of Series A Convertible Preferred Stock and warrants to purchase 2,000,000 shares of common stock. Each share of Series A Convertible Preferred Stock had a purchase price of $1,000.00, representing 100% of the stated value of each share of preferred stock, resulting in gross proceeds of approximately $6 million, before deducting financial advisory fees and other estimated offering expenses. In connection with the private placement offering, the Company's common stock has commenced trading on the Nasdaq Capital Market, under the trading symbol COSM.

Cosmos Holdings Announces Closing of $6 Million Private Placement of Convertible Preferred Stock and Start of Trading on the Nasdaq

CHICAGO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc.  (“the Company") (OTCQX:  COSM ), an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, today provided a business update with respect to its progress towards its direct listing efforts on the Nasdaq Capital Markets.

Cosmos Holdings Announces Shareholder Approval of Private Offering

CHICAGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the Company") (OTCQX: COSM ), an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, today provided a business update and reported financial results for the third quarter ended September 30, 2021.

Cosmos Holdings Achieves Positive Adjusted Net Income and Positive Adjusted EBITDA for the Third Quarter of 2021

CHICAGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the Company") (OTCQX: COSM ), an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, today announced that it has integrated SSI SCHAEFER's A-Frame Automated Robotic Picking System (“A-Frame”) into their pharmaceutical logistic center, CosmoFarm, a wholly owned subsidiary of Cosmos. The fully automated fulfillment system is designed to process complex orders with precision and speed, leading to increased performance while drastically lowering error rates. The system can process up to 40,000 products per hour and can accommodate a variety of packaging shapes and sizes. CosmoFarm's automated logistic center can be viewed here.

Cosmos Holdings Announces Installation of State-of-the-Art Automated Fulfillment System to Maximize the Productivity of CosmoFarm's Pharmaceutical Logistic Center in Athens, Greece

Ault Global Holdings Inc (NYSE: DPW) subsidiary entered into agreements for investments of ~$5.5 million in pharmaceutical company Cosmos Holdings, Inc. (OTC: COSM). The first investment, a convertible promissory note, resulted in immediate net proceeds of ~$500,000.

Cosmos Holdings Secures $5.5M Investment From Ault Global

Received initial bridge financing for proceeds of approximately $500,000 plus an additional $5.0 million of Series A Preferred Stock upon approval of Nasdaq listing Received initial bridge financing for proceeds of approximately $500,000 plus an additional $5.0 million of Series A Preferred Stock upon approval of Nasdaq listing

UPDATE - Cosmos Holdings Secures Approximately $5.5 Million Investment from Ault Global Holdings

Cosmos Holdings Secures Approximately $5.5 Million Investment from Ault Global Holdings

CHICAGO, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the Company") (OTCQX: COSM ), an international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, and an extensive, established European Union distribution network, today announced that the Company has entered into a debt exchange agreement with its senior lender (Lender) to further reduce the Company's debt. Under the terms of the agreement, the Company will issue the Lender 321,300 shares of common stock at $5.00 per share in exchange for the principal amount of debt of EUR $1.35 million (US $1.60 million). An additional EUR $1.00 million of debt (US $1.19 million) will be converted effective upon approval of listing of the Company's common stock to Nasdaq Capital Market in exchange for 238,000 shares of common stock at $5.00 per share, or at market value upon listing if the price is above $5.00 per share at the time of conversion. With this conversion, the Company has reduced the remaining balance of its senior debt to EU $350,000 (US $414,000).

Cosmos Holdings Announces Voluntary Conversion of Debt to Equity by the Company's Senior Lender, Further Enhancing the Balance Sheet

CHICAGO, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the Company") (OTCQX: COSM ), international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and an extensive, established European Union distribution network, today provided a business update and reported financial results for the second quarter ended June 30, 2021.

Cosmos Holdings Reports 15.8% Year-Over-Year Growth and 27.8% Sequential Increase in Revenue for the Second Quarter of 2021

Company Partners with Leading China E-Commerce Solutions Provider REMAI to Launch Sky Premium Life Products on Tmall Global Company Partners with Leading China E-Commerce Solutions Provider REMAI to Launch Sky Premium Life Products on Tmall Global

Cosmos Holdings to Open Flagship Store on Alibaba's Tmall Global, World's Largest Cross-Border E-Commerce Marketplace with 500M Monthly Active Users

CEO has converted $4.0 million of the Company's debt to date; the conversion price represents a premium to market CEO has converted $4.0 million of the Company's debt to date; the conversion price represents a premium to market

Cosmos Holdings CEO Greg Siokas Converts an Additional $1.25 Million of Debt into Common Stock at $6.00 Per Share

The conversion price represents a premium to market The conversion price represents a premium to market

Cosmos Holdings CEO Greg Siokas Converts an Additional $1.0 Million of Debt into Common Stock at $6.00 Per Share

First Phase Launches Sky Premium Life Products on Amazon and eBay; Second Phase Launch Includes Brick & Mortar Stores

Cosmos Holdings Signs Exclusive Distribution Agreement with Mediprovita GbR for Launch of Sky Premium Life Products in Germany and Austria

CHICAGO, July 01, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the Company") (OTCQX: COSM ), an international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and an extensive, established European Union distribution network, today announced that it has appointed finance veteran Alexi Papaconstantinou to the Company's Advisory Board.

Cosmos Holdings Appoints Finance Veteran Alexi Papaconstantinou to its Advisory Board

Cosmos Holdings CEO Greg Siokas Converts $3.0 Million of Debt into Common Stock at $6.00 Per Share

CHICAGO, May 18, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the Company") (OTCQX: COSM ), a vertically integrated, international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and an extensive, established European Union distribution network, today provided a business update and reported financial results for the first quarter ended March 31, 2021.

Cosmos Holdings Provides First Quarter 2021 Business Update; Reports 89% Year-Over-Year and 60% Sequential Increase in Nutraceutical Business

Marks First Step in Global E-Commerce Strategy; Reaffirms Plans to Enter New European and Global Markets in 2021 Marks First Step in Global E-Commerce Strategy; Reaffirms Plans to Enter New European and Global Markets in 2021

Cosmos Holdings to Launch Sky Premium Life Nutritional Supplements on Amazon UK

CHICAGO, April 16, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the Company") (OTCQX: COSM ), a vertically integrated, international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and an extensive, established European Union distribution network, today provided a business update and reported financial results for the full year ended December 31, 2020.

Cosmos Holdings Reports Revenue Growth of 40% to a Record $55.4 Million and Achieves Profitability for 2020

King Eros supplement formula developed to improve sexual health and men's libido

Cosmos Holdings Launches Proprietary King Eros and Queen Venus Supplements for Enhanced Libido

New proprietary formula for the symptomatic relief of pain and irritated sore throat

Cosmos Holdings Launches Mosept-Oral Antiseptic Spray Designed to be Effective Against Bacteria and Certain Viral Pathogens

New Proprietary Dietary Supplement Contributes to Normal Bone and Cartilage Health and Joint Flexibility

Cosmos Holdings Launches Osteodome in EU

CHICAGO, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the company") (OTCQX: COSM), a vertically integrated international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and an extensive, established EU distribution network, today announced the launch of a new, proprietary enhanced dietary supplement, Bodyguard, a targeted action formula for strengthening the immune system and reducing fatigue.

News for Cosmos Holdings Stock (COSM)